Chair, Tempest Therapeutics
Stephen Brady is the President & CEO of Claris Biotherapeutics and has nearly 30 years of operational, transactional, and board experience spanning corporate strategy, M&A, BD, and finance across public and private life sciences companies. Prior to Claris, Mr. Brady was the Board Chair and CEO of Tempest Therapeutics, and prior to this position, he was EVP of strategy and finance at Immune Design and played a key role in the company’s IPO, financings, BD deals, and eventual sale to Merck. Earlier, he held progressively senior roles at several biopharmaceutical companies, including VP of corporate development at Proteolix. In this position, Mr. Brady led Proteolix’s BD and strategic efforts that culminated in the sale to Onyx Pharmaceuticals. Proteolix’s lead asset, Kyprolis® (carfilzomib), subsequently became a principal driver of Amgen’s $10.4 billion acquisition of Onyx. Mr. Brady currently serves on the Board of Claris and the Biotechnology Innovation Organization (BIO).